Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) Therapy

NCT00149942 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Kidney Transplantation
Liver Transplantation

Interventions

DRUG: Enteric-coated Mycophenolate sodium (EC-MPS)

Sponsor

Novartis